IO Biotech, Inc.

TickerCurrent Price% Daily ChangeVolume (1,000s)Average Volumn (1,000s)Market Cap (Millions)1/2/2024 Price% Change Since Inception 1/2/2024
IOBT$1.7610%484151$116$1.91-7.9%

Contact Information

IO Biotech, Inc.
Ole Maaløes Vej 3
Copenhagen N
Copenhagen 2200
Denmark

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.